Business, energy, technology, markets and global industry news from Business News Today

molecular response

PharmaDeviceNews molecular response
Representative image of an oncologist reviewing melanoma imaging and molecular cancer data, reflecting Natera’s Signatera collaboration with Diakonos Oncology and the growing role of ctDNA monitoring in refractory melanoma immunotherapy trials.
Medical Devices & Diagnostics

Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development

Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.

Read More